To date, muscle function, and in particular that of the lower extremity, in OI type IV has not been investigated systematically. This study now assesses upper and lower extremity muscle function ...

A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...

There are no FDA-approved therapies for the treatment of OI.

Topline data were announced from two phase 3 studies evaluating setrusumab in patients with osteogenesis imperfecta.

Maybe you heard about it after watching the Samuel L. Jackson movie "Unbreakable." Or maybe after binging Season 11 of "Grey's Anatomy." Or maybe the words "osteogenesis imperfecta," or "OI," don't ...

Trial results show setrusumab reduces the incidence of fracture and increases bone density and formation. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

Osteogenesis Imperfecta (OI) is a heritable disorder characterized by increased bone fragility. In OI Type IV muscle weakness has important functional consequences. Children and adolescents with OI ...

Osteogenesis imperfecta type 3 is an inherited (genetic) bone disorder that is present at birth, according to John Hopkins Medicine, which notes that it is a lifelong condition. Furthermore, there is ...

Osteogenesis imperfecta is a clinically and genetically heterogeneous group of inherited connective tissue disorders in which bone fragility is the predominant feature. Cultured dermal fibroblasts ...